Rev03
Update: Dec,14,2021

DATASHEET

IL-17F, Human

Cat. No.: Z02713

Product Introduction

Species	Human
Protein Construction	Expressed with an N-terminal Met. **IL-17F (Arg31-Gln163) Accession # Q96PD4**
Purity	> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC
Endotoxin Level	< 1 EU/μg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The ED_{50} as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 20.0 ng/ml, corresponding to a specific activity of > 5.0×10^4 IU/mg.
Expression System	E. coli
Theoretical Molecular Weight	30.1 kDa
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.2, with trehalose.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 4 mM HCl up to 100 μg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background

Target Background : Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of $CD4^+$ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis.

Synonyms : Interleukin-17F; IL17F

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

GenScript USA, Inc.
860 Centennial Ave. Piscataway, NJ 08854
Tel: 1-732-885-9188